The effect of antihypertensive agents on new-onset diabetes mellitus: Time to amend the guidelines?

American Journal of Cardiovascular Drugs

Volumn 6, Issue 3, 2006, Pages 139-147

  Aksnes, Tonje Amb ^a   Kjeldsen, Sverre Erik ^a   Mancia, Giuseppe ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN SENSITIZING AGENT; LOOP DIURETIC AGENT; LOSARTAN; NATEGLINIDE; NIFEDIPINE; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAMIPRIL; ROSIGLITAZONE; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FACTORIAL DESIGN; FOLLOW UP; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INSULIN RELEASE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATHOGENESIS; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIURETICS; HOMEOSTASIS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33745646095     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606030-00001     Document Type: Review

References (72)

1. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005 Jul; 181 (1): 143-8
2. International Diabetes Federation. IDF worldwide definition of the metabolic syndrome [online]. Available from URL: http://www.idf.org/home/index. cfm?node=1429 [Accessed 2006 May 5]
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 Apr; 24 (4): 683-9
4. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991 Mar; 14 (3): 173-94
5. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004 May; 286 (5): H1597-1602
6. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003 Apr; 20 (4): 255-68
7. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001 Jan 2; 134 (1): 1-11
8. Leiter LA, Abbott D, Campbell NR, et al. Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Preven-tion and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999 May 4; 160 (9 Suppl.): S7-12
9. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001 Nov; 38 (5): 1112-7
10. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001 Jan 4; 344 (1): 3-10
11. He J, Whelton PK. What is the role of dietary sodium and potassium in hyperten-sion and target organ injury? Am J Med Sci 1999 Mar; 317 (3): 152-9
12. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med 1998 Dec; 20 (4): 441-8
13. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996 Feb 8; 334 (6): 374-81
14. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004 Jan; 27 (1): 247-55
15. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000 Mar 30; 342 (13): 905-12
16. Aksnes TA, Reims HM, Kjeldsen SE, et al. Antihypertensive treatment and new-onset diabetes mellitus. Curr Hypertens Rep 2005 Aug; 7 (4): 298-303
17. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
18. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000 Jul 29; 356 (9227): 366-72
19. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-31
20. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004 May; 43 (5): 963-9
21. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated hypertension with and without diabetes. Am J Cardiol 2005 Jan 1; 95 (1): 29-35
22. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 Dec 13; 414 (6865): 782-7
23. Padwal R, Mamdani M, Alter DA, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004 Oct; 27 (10): 2458-63
24. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003 Sep 6; 362 (9386): 759-66
25. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001 Oct 17; 286 (15): 1882-5
26. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 May; 21 (5): 875-86
27. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003 Mar 11; 107 (9): 1291-6
28. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004 Nov 11; 351 (20): 2058-68
29. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003 Aug; 21 (8): 1563-74
30. Reid CM, Johnston CI, Ryan P, et al. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study. Am J Hypertens 2003 May; 16 (5 Suppl. 1): A11
31. Niklason A, Hedner T, Niskanen L, et al. Development of diabetes is retarded by ACE inhibition in hypertensive patients: a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004 Mar; 22 (3): 645-52
32. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002 Sep; 20 (9): 1879-86
33. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbid-ity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999 Nov 20; 354 (9192): 1751-6
34. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10; 366 (9489): 895-906
35. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coro-nary artery disease. The International Verapamil-Trandolapril Study (IN-VEST): a randomized controlled trial. JAMA 2003 Dec 3; 290 (21): 2805-16
36. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000 Jul 29; 356 (9227): 359-65
37. Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser 1985; 727: 1-113
38. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 Jul; 15 (7): 539-53
39. Gerstein HC, Yusuf S, Holman R, et al. Rationale, design and recruitment charac-teristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004 Sep; 47 (9): 1519-27
40. NAVIGATOR information site [online]. Available from URL: http://www.bioportfolio.com/news/novartis1.htm [Accessed 2004 Oct 24]
41. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004 Jul; 148 (1): 52-61
42. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992 Jul; 15 (7): 815-9
43. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting: enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb 13; 348 (7): 583-92
44. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. J Am Coll Cardiol 2005 Sep; 46 (5): 821-6
45. Cheung BMY, Cheung GTY, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006 Jan; 20 (1): 37-43
46. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randiomised clinical trials. Diabetes Metab 2004 Dec; 30 (6): 487-96
47. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003 Jul; 196 (1): 171-9
48. Jacob S, Henriksen EJ, Fogt DL, et al. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996 May; 45 (5): 535-41
49. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002 Nov; 40 (5): 609-11
50. Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994; 24 Suppl. 3: S61-9
51. Tikellis C, Wookey PJ, Candido R, et al. Improved islet morphology after blockade of the renin: angiotensin system in the ZDF rat. Diabetes 2004 Apr; 53 (4): 989-97
52. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998 Feb; 41 (2): 127-33
53. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004 May; 43 (5): 993-1002
54. Pitre M, Gaudreault N, Santure M, et al. Isradipine and insulin sensitivity in hypertensive rats. Am J Physiol 1999 Jun; 276 (6 Pt 1): E1038-48
55. Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens Suppl 1987 Dec; 5 (4): S81-104
56. Hood S, Cannon J, Foo R, et al. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005 Jan; 5 (1): 55-60
57. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989 Sep 28; 321 (13): 868-73
58. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965 Nov 18; 273 (21): 1135-43
59. Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994 Jul 23; 309 (6949): 226-30
60. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983 Feb; 32 (2): 106-11
61. Shamiss A, Carroll J, Peleg E, et al. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 1995 Mar; 8 (3): 276-81
62. Cerasi E, Luft R, Efendic S. Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol (Copenh) 1972 Feb; 69 (2): 335-46
63. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998 Oct; 11 (10): 1258-65
64. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
65. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-92
66. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
67. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hyperten-sion: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18 (3): 139-85
68. Sever P. The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J Hum Hypertens 1995 Jul; 9 Suppl. 2: S33-6
69. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001 Jan; 15 (1): 17-25
70. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004 Aug; 22 (8): 1453-8
71. NICE and BHS confirm review of hypertension guidelines [online]. Available from URL: http: //www.nice.org.uk/page.aspx?.o = 276966 [Accessed 2005 Oct 26]
72. Kjeldsen SE, Reims H, Fagard R, et al. Hypertension. In: Camm AJ, Lüscher TF, Serruys P, editors. European Society of Cardiology textbook of cardiovascular medicine. 2005 ed. Oxford: Blackwell Publishing, 2005